Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBM
Public ClinicalTrials.gov record NCT00004146. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Clinical and Pharmacologic Study of Radiation Therapy and CAI (Carboxy-Amido Triazole) in Adults With Newly Diagnosed Glioblastoma Multiforme
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. Phase II trial to study the effectiveness of carboxyamidotriazole plus radiation therapy in treating patients who have newly diagnosed supratentorial glioblastoma multiforme.
Study identification
- NCT ID
- NCT00004146
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 55 participants
Conditions and interventions
Interventions
- radiation therapy Radiation
- carboxyamidotriazole Drug
- pharmacological study Other
Radiation · Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2000 (Type not available)
- Primary completion
- Jan 2010 (Actual)
- Completion
- Jan 2010 (Actual)
- Last update posted
- May 8, 2015
2000 – 2010
United States locations
- U.S. sites
- 8
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama Birmingham | Birmingham | Alabama | 35294 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Emory University/Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| Johns Hopkins University | Baltimore | Maryland | 21287 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| Wake Forest University | Winston-Salem | North Carolina | 27157 | — |
| University of Pennsylavania/Abramson Cancer Center | Philadelphia | Pennsylvania | 19104 | — |
| University of Texas Health Science Center at San Antonio | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00004146, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 8, 2015 · Synced Oct 31, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00004146 live on ClinicalTrials.gov.